Literature DB >> 21080205

Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.

James A Platts1, Giuseppe Ermondi, Giulia Caron, Mauro Ravera, Elisabetta Gabano, Luca Gaviglio, Giorgio Pelosi, Domenico Osella.   

Abstract

We report the results of the quantitative structure-property relationship analysis of 31 Pt(IV) complexes, for three of which the synthesis is reported for the first time. The X-ray structural analysis of one complex of the series was performed to demonstrate that the PM6 semiempirical method satisfactorily reproduces key features of the geometry of the complexes investigated. Molecular properties extracted from such calculations were then used to construct models of experimental data such as electrochemical peak potentials (evaluated by cyclic voltammetry) and the octanol-water partition coefficient (evaluated by a reversed-phase high performance liquid chromatography method), which are key aspects in the design of such Pt(IV) complexes as potential anticancer prodrugs. Statistically accurate models for both properties were found using combinations of surface areas, orbital energies, dipole moments, and atomic partial charges. These models could form the basis of virtual screening of potential drug molecules, allowing the prediction of properties, closely related to the antiproliferative activity of Pt(IV) complexes, directly from calculated data.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080205     DOI: 10.1007/s00775-010-0731-1

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  30 in total

1.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Authors:  C M Giandomenico; M J Abrams; B A Murrer; J F Vollano; M I Rheinheimer; S B Wyer; G E Bossard; J D Higgins
Journal:  Inorg Chem       Date:  1995-03       Impact factor: 5.165

Review 2.  The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.

Authors:  Angel M Montaña; Consuelo Batalla
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

3.  Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.

Authors:  Katherine S Lovejoy; Stephen J Lippard
Journal:  Dalton Trans       Date:  2009-10-01       Impact factor: 4.390

Review 4.  Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships.

Authors:  T Braumann
Journal:  J Chromatogr       Date:  1986-11-14

5.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

6.  The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes.

Authors:  James A Platts; Steven P Oldfield; Maria M Reif; Alessandra Palmucci; Elisabetta Gabano; Domenico Osella
Journal:  J Inorg Biochem       Date:  2006-07       Impact factor: 4.155

7.  A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).

Authors:  R Kizu; T Nakanishi; K Hayakawa; A Matsuzawa; M Eriguchi; Y Takeda; N Akiyama; T Tashiro; Y Kidani
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

8.  Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake.

Authors:  Steven P Oldfield; Matthew D Hall; James A Platts
Journal:  J Med Chem       Date:  2007-09-27       Impact factor: 7.446

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination.

Authors:  Michael R Reithofer; Seied M Valiahdi; Michael A Jakupec; Vladimir B Arion; Alexander Egger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-11-22       Impact factor: 7.446

View more
  6 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

2.  Elusive Intermediates in the Breakdown Reactivity Patterns of Prodrug Platinum(IV) Complexes.

Authors:  Davide Corinti; Maria Elisa Crestoni; Simonetta Fornarini; Fortuna Ponte; Nino Russo; Emilia Sicilia; Elisabetta Gabano; Domenico Osella
Journal:  J Am Soc Mass Spectrom       Date:  2019-04-12       Impact factor: 3.109

3.  Studies on log Po/w of quinoxaline di-N-oxides: a comparison of RP-HPLC experimental and predictive approaches.

Authors:  Elsa Moreno; Elisabetta Gabano; Enrique Torres; James A Platts; Mauro Ravera; Ignacio Aldana; Antonio Monge; Silvia Pérez-Silanes
Journal:  Molecules       Date:  2011-09-13       Impact factor: 4.411

4.  Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.

Authors:  Hristo P Varbanov; Michael A Jakupec; Alexander Roller; Frank Jensen; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2012-12-27       Impact factor: 7.446

5.  Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands.

Authors:  Yan Peng; Min-Min Zhang; Zhen-Feng Chen; Kun Hu; Yan-Cheng Liu; Xia Chen; Hong Liang
Journal:  Bioinorg Chem Appl       Date:  2013-03-05       Impact factor: 7.778

6.  Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells.

Authors:  Ulrike Olszewski; Ernst Ulsperger; Klaus Geissler; Gerhard Hamilton
Journal:  J Exp Pharmacol       Date:  2011-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.